Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: okamura s. Cancers (Basel). 2021 Jan 5;13(1):160. doi: 10.3390/cancers13010160. Cancers (Basel). 2021. PMID: 33466496 Free PMC article.
Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching.
Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Kawaguchi A, Koga H, Yokokura Y, Torimura T. Shimose S, et al. Among authors: okamura s. Hepatol Res. 2019 Aug;49(8):919-928. doi: 10.1111/hepr.13348. Epub 2019 May 13. Hepatol Res. 2019. PMID: 30969006
Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
Shimose S, Kawaguchi T, Iwamoto H, Tanaka M, Miyazaki K, Ono M, Niizeki T, Shirono T, Okamura S, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: okamura s. Nutrients. 2020 Apr 13;12(4):1076. doi: 10.3390/nu12041076. Nutrients. 2020. PMID: 32295043 Free PMC article.
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events.
Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, Okamura S, Noda Y, Kamachi N, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Sakai M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T. Iwamoto H, et al. Among authors: okamura s. Cancers (Basel). 2020 Apr 19;12(4):1010. doi: 10.3390/cancers12041010. Cancers (Basel). 2020. PMID: 32325921 Free PMC article.
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study.
Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: okamura s. Cancers (Basel). 2020 Jul 11;12(7):1867. doi: 10.3390/cancers12071867. Cancers (Basel). 2020. PMID: 32664489 Free PMC article.
Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis.
Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Nakano M, et al. Among authors: okamura s. Hepatol Commun. 2020 Jun 20;4(8):1218-1228. doi: 10.1002/hep4.1535. eCollection 2020 Aug. Hepatol Commun. 2020. PMID: 32766480 Free PMC article.
Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma.
Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwara M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, Torimura T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan. Iwamoto H, et al. Among authors: okamura s. Cancers (Basel). 2021 Feb 5;13(4):646. doi: 10.3390/cancers13040646. Cancers (Basel). 2021. PMID: 33562793 Free PMC article.
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwara A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T, On Behalf Of The Kurume Liver Cancer Study Group Of Japan. Iwamoto H, et al. Among authors: okamura s. Cancers (Basel). 2021 Jun 3;13(11):2786. doi: 10.3390/cancers13112786. Cancers (Basel). 2021. PMID: 34205099 Free PMC article.
862 results